Except for C-C chemokine receptor 7 expression, monocyte-derived dendritic cells from patients with multiple sclerosis are functionally comparable to those of healthy controls

Cytotherapy

Volumn 16, Issue 7, 2014, Pages 1024-1030

  Nuyts, Amber H ^a   Ponsaerts, Peter ^a   Van Tendeloo, Viggo F I ^a   Lee, Wai Ping ^a   Stein, Barbara ^a   Nagels, Guy ^b   D'hooghe, Marie B ^b   Willekens, Barbara ^c   Cras, Patrick ^c   Wouters, Kristien ^d   Goossens, Herman ^a   Berneman, Zwi N ^a   Cools, Nathalie ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b National Multiple Sclerosis Center   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Dendritic cells; Immunotherapy; Multiple sclerosis; T cell activation

Indexed keywords

B7 ANTIGEN; CD209 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HLA DR ANTIGEN;

ADULT; AGED; ARTICLE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MONOCYTE DERIVED DENDRITIC CELL; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINATION; BIOSYNTHESIS; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOLOGY; T LYMPHOCYTE;

ADULT; AGED; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; RECEPTORS, CCR7; T-LYMPHOCYTES; VACCINATION;

EID: 84901998115     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.02.016     Document Type: Article

References (41)

1. Aktas O., Kieseier B., Hartung H.P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010, 33:140-152.
2. Nylander A., Hafler D.A. Multiple sclerosis. JClin Invest 2012, 122:1180-1188.
3. Koch M.W., Metz L.M., Kovalchuk O. Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol 2013, 9:35-43.
4. Cools N., Ponsaerts P., Van Tendeloo V.F., Berneman Z.N. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. JLeukoc Biol 2007, 82:1365-1374.
5. Bakdash G., Sittig S.P., van Dijk T., Figdor C.G., de Vries I.J. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol 2013, 4:53.
6. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
7. Kalinski P., Hilkens C.M., Wierenga E.A., Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999, 20:561-567.
8. Cools N., Van Tendeloo V.F., Smits E.L., Lenjou M., Nijs G., Van Bockstaele D.R., et al. Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells. JCell Mol Med 2008, 12:690-700.
9. de Jong E.C., Smits H.H., Kapsenberg M.L. Dendritic cell-mediated T cell polarization. Springer Semin Immunopathol 2005, 26:289-307.
10. Cools N., Petrizzo A., Smits E., Buonaguro F.M., Tornesello M.L., Berneman Z., et al. Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?. Immunotherapy 2011, 3:1203-1222.
11. Nuyts A., Lee W., Bashir-Dar R., Berneman Z., Cools N. Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?. Mult Scler 2013, 19:995-1002.
12. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. JExp Med 2001, 193:233-238.
13. Thomas R., Street S., Ramnoruth N., Pahau H., Law S., Brunck M., et al. Feasibility, safety and clinical effects of a single intradermal administration of autologous tolerising dendritic cells exposed to citrullinated peptides in patients with rheumatoid arthritis. Arthritis Rheum 2011, 63:S946.
14. Giannoukakis N., Phillips B., Finegold D., Harnaha J., Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011, 34:2026-2032.
15. Thewissen K., Nuyts A.H., Deckx N., Wijmeersch B.V., Nagels G., D'Hooghe M., et al. Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. Mult Scler 2014, 20:548-557.
16. Karni A., Abraham M., Monsonego A., Cai G., Freeman G.J., Hafler D., et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. JImmunol 2006, 177:4196-4202.
17. Pashenkov M., Teleshova N., Kouwenhoven M., Kostulas V., Huang Y.M., Soderstrom M., et al. Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis. Clin Exp Immunol 2002, 127:519-526.
18. Schwab N., Zozulya A.L., Kieseier B.C., Toyka K.V., Wiendl H. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis. JImmunol 2010, 184:5368-5374.
19. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001, 50:121-127.
20. Hellings N., Baree M., Verhoeven C., D'Hooghe M.B., Medaer R., Bernard C.C., et al. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. JNeurosci Res 2001, 63:290-302.
21. Raïch-Regue D., Grau-Lopez L., Naranjo-Gomez M., Ramo-Tello C., Pujol-Borrell R., Martinez-Caceres E., et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012, 42:771-782.
22. Huang Y.M., Kouwenhoven M., Jin Y.P., Press R., Huang W.X., Link H. Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression. Mult Scler 2001, 7:95-99.
23. Bartosik-Psujek H., Tabarkiewicz J., Pocinska K., Stelmasiak Z., Rolinski J. Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis. Mult Scler 2010, 16:1513-1516.
24. Hussien Y., Sanna A., Soderstrom M., Link H., Huang Y.M. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. JNeuroimmunol 2001, 121:102-110.
25. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., Patsopoulos N.A., Moutsianas L., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
26. Verdijk P., Aarntzen E.H., Lesterhuis W.J., Boullart A.C., Kok E., van Rossum M.M., et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009, 15:2531-2540.
27. Sanchez-Sanchez N., Riol-Blanco L., Rodriguez-Fernandez J.L. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. JImmunol 2006, 176:5153-5159.
28. Huang Y.M., Stoyanova N., Jin Y.P., Teleshova N., Hussien Y., Xiao B.G., et al. Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10. Clin Exp Immunol 2001, 124:306-314.
29. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999, 122:2089-2100.
30. Diaz-Villoslada P., Shih A., Shao L., Genain C.P., Hauser S.L. Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen. JNeuroimmunol 1999, 99:36-43.
31. Ewing C., Bernard C.C. Insights into the aetiology and pathogenesis of multiple sclerosis. Immunol Cell Biol 1998, 76:47-54.
32. Van der Aa A., Hellings N., Bernard C.C., Raus J., Stinissen P. Functional properties of myelin oligodendrocyte glycoprotein-reactive T cells in multiple sclerosis patients and controls. JNeuroimmunol 2003, 137:164-176.
33. Fredrikson S., Soderstrom M., Hillert J., Sun J.B., Kall T.B., Link H. Multiple sclerosis: occurrence of myelin basic protein peptide-reactive T cells in healthy family members. Acta Neurol Scand 1994, 89:184-189.
34. Ota K., Matsui M., Milford E.L., Mackin G.A., Weiner H.L., Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990, 346:183-187.
35. Kerlero de Rosbo N., Hoffman M., Mendel I., Yust I., Kaye J., Bakimer R., et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 1997, 27:3059-3069.
36. Wallstrom E., Khademi M., Andersson M., Weissert R., Linington C., Olsson T. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Eur J Immunol 1998, 28:3329-3335.
37. Jingwu Z., Medaer R., Hashim G.A., Chin Y., van den Berg-Loonen E., Raus J.C. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann Neurol 1992, 32:330-338.
38. Bielekova B., Sung M.H., Kadom N., Simon R., McFarland H., Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. JImmunol 2004, 172:3893-3904.
39. von Budingen H.C., Tanuma N., Villoslada P., Ouallet J.C., Hauser S.L., Genain C.P. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. JClin Immunol 2001, 21:155-170.
40. Weiner H.L. Immunosuppressive treatment in multiple sclerosis. JNeurol Sci 2004, 223:1-11.
41. Frohman E.M., Stuve O., Havrdova E., Corboy J., Achiron A., Zivadinov R., et al. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol 2005, 62:1519-1530.